Cardioxyl Buy To Resuscitate Bristol's CV Pipeline?
This article was originally published in Scrip
You may also be interested in...
Bristol says its checkpoint immunotherapies can hold the lead in renal cell carcinoma, despite increasing competition.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.